GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and Relation Therapeutics, using their Lab in the Loop platform to discover novel targets for osteoarthritis, systemic sclerosis and other fibrotic mechanisms, supporting data-tech driven approach in respiratory, immunology and inflammation; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, the United Kingdom.

Period	TotalRevenue
2015-12-31	$23.92B
2016-12-31	$27.89B
2017-12-31	$30.19B
2018-12-31	$30.82B
2019-12-31	$33.75B
2020-12-31	$34.10B
2021-12-31	$34.11B
2022-12-31	$29.32B
2023-12-31	$30.33B
2024-12-31	$31.38B

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GSK	$55.84	+0.00%	3.85M
3
4
5

GSK plc American Depositary Shares (Each representing two) (GSK) Revenue History

Revenue Data

Get GSK plc American Depositary Shares (Each representing two) Data in Excel

More GSK Financial Data